Struggling Teva Ponders Over Offloading Its Cancer Portfolio To Reduce Debt
Teva Pharmaceutical Industries Ltd., the Israeli drugmaker seeking to cut debt after an acquisition spree, is exploring a sale of its specialty cancer treatments, according to people familiar with the matter.
Teva is speaking with financial advisers about the possible sale of the oncology business, which includes treatments for leukemia and a slow-growing form of lymphoma, the people said, asking not to be identified because the deliberations are private. The business could attract private equity bidders and other companies, they said.
Teva is speaking with financial advisers about the possible sale of the oncology business, which includes treatments for leukemia and a slow-growing form of lymphoma, the people said, asking not to be identified because the deliberations are private. The business could attract private equity bidders and other companies, they said.